Jazz Pharmaceuticals revenue and financials
$231.39Change from previous close: −1.97%Absolute change: −$4.65
In the fiscal year ended December 2025, Jazz Pharmaceuticals reported revenue of $4.27B (+4.88% year over year). The net loss was $356.15M.
Fiscal year ending in December. Sources and method on the page Methodology and sources.
At a glance
- Revenue growth
- +4.88%
- 2025 vs 2024
- Net margin
- -8.3%
- 2024: 13.8%
Financial data
Amounts in millions of USD; per-share values in USD; shares in millions.
| Item | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenue | 4,268 | 4,069 | 3,834 | 3,659 | 3,094 | 2,364 | 2,162 | 1,891 | 1,619 | 1,488 |
| Cost of revenue | 355 | 311 | 284 | 267 | 218 | — | — | — | — | — |
| Gross profit | 3,912 | 3,758 | 3,550 | 3,392 | 2,877 | — | — | — | — | — |
| Selling, general and administrative | 1,498 | 1,416 | 1,307 | 1,399 | 1,399 | — | — | — | — | — |
| Research and development | 741 | 851 | 818 | 555 | 476 | — | 300 | 227 | 198 | 162 |
| Operating income | -430 | 717 | 579 | -65.5 | 170 | 378 | 532 | 615 | 529 | 592 |
| EBIT | 1,018 | 864 | 816 | 839 | 475 | — | — | — | — | — |
| EBITDA | 1,714 | 1,524 | 1,455 | 1,469 | 1,028 | — | — | — | — | — |
| Interest expense | 281 | 344 | 355 | 300 | 281 | — | — | — | — | — |
| Pre-tax income | -629 | 469 | 295 | -383 | -114 | — | — | — | — | — |
| Income tax | -272 | -91.4 | -120 | -159 | 216 | 33.5 | -73.2 | 80.2 | -47.7 | 135 |
| Net income | -356 | 560 | 415 | -224 | -330 | 239 | 523 | 447 | 488 | 397 |
| Net income to common shareholders | -356 | 560 | 415 | -224 | -330 | — | — | — | — | — |
| Basic EPS | -5.84 | 9.06 | 6.55 | -3.58 | -5.52 | 4.28 | 9.22 | 7.45 | 8.13 | 6.56 |
| Diluted EPS | -5.84 | 8.65 | 6.10 | -3.58 | -5.52 | 4.22 | 9.09 | 7.30 | 7.96 | 6.41 |
| Average shares (basic) | 61.0 | 61.8 | 63.3 | 62.5 | 59.7 | — | — | — | — | — |
| Average shares (diluted) | 61.0 | 66.0 | 72.1 | 62.5 | 59.7 | 56.5 | 57.6 | 61.2 | 61.3 | 61.9 |